AbCellera Biologics (ABCL) Accumulated Depreciation (2020 - 2022)
AbCellera Biologics' (ABCL) quarterly Accumulated Depreciation came in at $18.5 million in Q4 2022, up 88.02% YoY from $9.8 million in Q4 2021, and up 17.4% on a QoQ basis from $15.7 million in Q3 2022.
AbCellera Biologics (ABCL) Accumulated Depreciation (2020 - 2022) Analysis & Trends
AbCellera Biologics (ABCL) has 3 years of Accumulated Depreciation data on file, last reported at $18.5 million in Q4 2022.
- Quarterly Accumulated Depreciation rose 88.02% year-over-year to $18.5 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $18.5 million (up 88.02% YoY) and the FY2022 annual result came in at $18.5 million, up 88.02% from the prior year.
- Accumulated Depreciation improved to $18.5 million in Q4 2022, from $15.7 million in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $18.5 million in Q4 2022 to a low of $5.6 million in Q4 2020.
- A 3-year average of $10.7 million and a median of $9.8 million in 2021 frame the typical range for Accumulated Depreciation.
- Annual changes were most pronounced in 2021 — Accumulated Depreciation soared 75.9% — and 2022, when it jumped 88.02%.
- Tracing ABCL's Accumulated Depreciation over 3 years: stood at $5.6 million in 2020, then soared by 75.9% to $9.8 million in 2021, then jumped by 88.02% to $18.5 million in 2022.
- The last three Accumulated Depreciation figures came in at $18.5 million (Q4 2022), $15.7 million (Q3 2022), and $13.2 million (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 18.48 Mn |
| Sep 30, 2022 | 15.74 Mn |
| Jun 30, 2022 | 13.22 Mn |
| Mar 31, 2022 | 11.21 Mn |
| Dec 31, 2021 | 9.83 Mn |
| Sep 30, 2021 | 8.51 Mn |
| Jun 30, 2021 | 7.34 Mn |
| Mar 31, 2021 | 6.29 Mn |
| Dec 31, 2020 | 5.59 Mn |